Hot Investor Mandate: Corporate Venture Arm of Major Corporation Invests in Therapeutics, Digital Health, and AI Applications Through Multiple Funds

2 Nov

A venture capital arm of a global conglomerate has several global offices including two sites in the US. In 2021, the firm raised a dedicated life science fund to invest in therapeutic and bioprocessing companies with flexibility of entering at different stages of development. The investment size varies depending on the opportunity. The firm is actively seeking new investment opportunities globally.

The firm will make new investments from both traditional funds and their new life science fund. The traditional funds invest in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The new life science fund is interested in therapeutics, particularly gene therapy, ADC technologies, RNA delivery platform technologies, and bioprocessing business that support these strategic areas of interest.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Leave a comment